ANB101 / Centessa, First Tracks Biotherapeutics, Eli Lilly - LARVOL DELTA

AnaptysBio Plans First Tracks Spin-Off as Jemperli Royalties Surge, Buybacks Possible (Yahoo Finance) - "...The company expects to create a new company, First Tracks Biotherapeutics, within 'a month or two'. Under the plan, the existing AnaptysBio name will remain with a lean, royalty-based business, while the majority of employees, labs, and development-stage assets will transfer to First Tracks....First Tracks will house development programs (ANB033, rosnilimab, ANB101) and receive a large portion of AnaptysBio’s ~$310 million cash..."

Commercial • dMMR • MSI-H • Endometrial Cancer

Biopharma Co Profile (GlobeNewswire) - "AnaptysBio...announced today that its Board of Directors approved plans to explore separating its business into two independent, publicly traded companies, each poised for strong, sustainable growth.....Upon completion, Biopharma Co will be a clinical-stage biotechnology company focused on the development and potential commercialization of innovative therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033 and ANB101."

Commercial • Immunology • Inflammation

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) - "ANB033 (CD122 antagonist): Enrollment ongoing for Phase 1a trial in healthy volunteers. Phase 1b indication to be disclosed at a 2025 R&D event. ANB101 (BDCA2 modulator): Phase 1a trial to initiate in healthy volunteers in Q1 2025....Research and development expenses were $42.6 million and $163.8 million for the three and twelve months ended December 31, 2024, compared to $33.5 million and $132.3 million for the three and twelve months ended December 31, 2023. The increase was due primarily to development costs for rosnilimab, ANB032, ANB033 and ANB101 offset by a decrease in development costs for imsidolimab."

Commercial • New P1 trial • Trial status • Immunology

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) - "Updates on Wholly Owned ICM Pipeline:...(i) ANB033 (anti-CD122 antagonist antibody): IND application accepted by FDA in July 2024; Phase 1 trial initiation in healthy volunteers anticipated in Q4 2024; (ii) ANB101 (BDCA2 modulator antibody): Plan to submit IND application in Q4 2024."

IND • New P1 trial • Inflammation

Modulation of cell migration and cell tracking of the gilthead seabream (Sparus aurata) SAF-1 cells by probiotics. (PubMed, Fish Shellfish Immunol) - "Furthermore, to increase our understanding of the genes involved in cell movement, the expression profile of ten structural proteins (α-1β tubulin, vinculin, focal adhesion kinase type, alpha-2 integrin, tetraspanin, integrin-linked kinase 1, tensin 3, tensin 4, paxillin, and light chain 2) was studied by real time-PCR. The expression of these genes was modulated as a function of the probiotic tested and the results indicate that CBS004 and SpPdp11 increase the movement of SAF-1 cells."

Journal • TNS3 • VCL

Centessa Pharmaceuticals Announces Third Quarter 2021 Financial Results and Business Updates (GlobeNewswire) - "Centessa Pharmaceuticals plc...today reported financial results for the quarter ended September 30, 2021, and provided a review of recent accomplishments and anticipated upcoming milestones....In 2H 2022, the Company expects to submit an Investigational New Drug ('IND') application with the U.S. Food and Drug Administration ('FDA') for CBS004 and commence a Phase 1 study shortly thereafter."

IND • Immunology • Lupus • Systemic Lupus Erythematosus • Systemic Sclerosis

Centessa Pharmaceuticals Announces Third Quarter 2021 Financial Results and Business Updates (GlobeNewswire) - "Capella Bioscience’s CBS004, an anti-BDCA2 mAb for Systemic & Cutaneous Lupus Erythematosus ('SLE/CLE') and Systemic Sclerosis ('SSc'): In 2H 2022, the Company expects to submit an Investigational New Drug ('IND') application with the U.S. Food and Drug Administration ('FDA') for CBS004 and commence a Phase 1 study shortly thereafter."

New P1 trial • Immunology • Systemic Sclerosis